Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
John de Groot(University of California, San Francisco), Amy B. Heimberger(Northwestern University)
Cited by 165
Related Papers
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
|Neuro-Oncology|2010|708
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
|JCI Insight|2016|454
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
|Neuro-Oncology|2017|427
Hypoxia Potentiates Glioma-Mediated Immunosuppression
|PLoS ONE|2011|219